Technology

At HighField, lipids are an integral part of the therapeutic

We create targeted treatments that recognize the complexities of people and disease

Our lead clinical development programs target cancer. Cancer therapeutics require a multilayered approach. The tumor microenvironment (TME) plays a pivotal role in the behavior and development of solid tumors. As the tumor cells proliferate, they have diverse interactions with surrounding tissues. Our lipid-based therapeutics address the TME to stop tumor growth.

We are also developing lipid nanoparticles (LNP) containing RNA for gene therapy These LNP-RNA complexes treat chronic autoimmune, metabolic and genetic diseases. LNP complexes are well known for immunization. However, our LNPs are different from those used for vaccines.

Vaccine-related LNPs are designed to disintegrate for short term use in the body and produce an immune reaction. However, HighField’s LNPs are tailored for stability, sustained circulation, minimum immune reaction and long term efficacy. This results in longer lasting production of greater amounts of the therapeutic proteins.

The Highfield Advantage

Our immuno-oncology and LNP platforms are built upon our unique capability to optimize components of a lipid system directed to specific disease tissue. Combined with our proprietary system that consistently produces very high quality lipid structures , HighField can produce therapeutics with maximum efficacy and safety.

Beating cancer with lipid-based therapeutics

On one level, we design our lipids to maximize their inherent targeting properties towards rapidly growing tissue, like cancer tissue. On another level, we enhance the targeting by attaching antibodies to the lipids to form immunoliposomes.

Our immunoliposomes offer greater payload capacity and flexibility than standard target therapeutics like antibody-drug conjugates (ADCs). The size and nature of the lipid assembly, targeting antibodies, drug payload and disease addressed are components driving the design of our therapeutics.

HighField has developed an iterative, continuous production process for lipid manufacture. This novel approach greatly improves quality and consistency.

Treating chronic and genetic diseases with LNP gene therapies

We are creating LNP-RNA complexes that produce therapeutic proteins in the body. These proteins treat chronic diseases such as autoimmune, genetic and metabolic disorders. Our LNP-RNA complexes create a steady long-term production of the therapeutic protein with little or no immune response.